Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.

Nagano S, Mori M, Kato A, Ono Y, Aoki K, Arima H, Takiuchi Y, Tabata S, Yanagita S, Matsushita A, Ishikawa T, Imai H, Takahashi T.

Intern Med. 2013;52(10):1101-5. Epub 2013 May 15.

2.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
3.

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Huang SY, Lin CW, Lin HH, Yao M, Tang JL, Wu SJ, Chen YC, Lu HY, Hou HA, Chen CY, Chou WC, Tsay W, Chou SJ, Tien HF.

Ann Hematol. 2014 Aug;93(8):1371-80. doi: 10.1007/s00277-014-2063-7. Epub 2014 Apr 1.

4.

[Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].

Fuchida S, Okano A, Hatsuse M, Murakami S, Haruyama H, Shimazaki C.

Rinsho Ketsueki. 2012 Nov;53(11):1937-9. Review. Japanese.

PMID:
23257677
5.

[IgM-lambda multiple myeloma presenting with systemic amyloidosis].

Higeta D, Yokohama A, Osaki Y, Tahara K, Mawatari M, Sekigami T, Koiso H, Saito T, Uchiumi H, Handa H, Karasawa M, Murakami H, Hirato J, Tsukamoto N, Nojima Y.

Rinsho Ketsueki. 2009 Dec;50(12):1711-4. Japanese.

PMID:
20068279
6.

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

Buda G, Orciuolo E, Galimberti S, Pelosini M, Petrini M.

Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22. No abstract available. Erratum in: Ann Hematol. 2011 Jul;90(7):863.

PMID:
21181162
7.

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E.

Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5.

PMID:
22763386
8.

[Chemotherapy for multiple myeloma].

Ishida T.

Nihon Rinsho. 2007 Dec;65(12):2280-4. Review. Japanese.

PMID:
18069273
9.

A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.

Takasu M, Tani C, Kaichi Y, Sakoda Y, Kiguchi M, Date S, Kuroda Y, Sakai A, Awai K.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):485-92. doi: 10.1016/j.clml.2014.07.009. Epub 2014 Aug 12.

PMID:
25190250
10.

Novel agents for relapsed and/or refractory multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Review.

PMID:
20010168
11.

[New treatment strategies for multiple myeloma].

Ozaki S.

Rinsho Ketsueki. 2009 Oct;50(10):1506-17. Review. Japanese. No abstract available.

PMID:
19915360
12.

[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].

Adam Z, Stork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Cermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer J.

Vnitr Lek. 2012 Dec;58(12):896-903. Czech.

PMID:
23427947
13.

Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.

Miyao K, Sakemura R, Sakai T, Tsushita N, Kato T, Niimi K, Ono Y, Sawa M.

Ann Hematol. 2014 Mar;93(3):529-30. doi: 10.1007/s00277-013-1835-9. Epub 2013 Jul 3. No abstract available.

PMID:
23820941
14.

Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.

Dasanu CA, Reale MA, Bauer F.

Leuk Res. 2010 Jul;34(7):e178-80. doi: 10.1016/j.leukres.2010.01.002. Epub 2010 Jan 15. No abstract available.

PMID:
20079532
15.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Islam A, Ambrus JL.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. doi: 10.1056/NEJMc086420. No abstract available.

16.

[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].

Adam Z, Sčudla V, Krejčí M, Cermáková Z, Pour L, Král Z.

Vnitr Lek. 2013 Jan;59(1):37-58. Review. Czech.

PMID:
23428001
17.

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A.

Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17. Erratum in: Blood. 2014 Jun 12;123(24):3843.

18.

Treatment of relapsed and refractory myeloma.

Kaufman J, Gleason C, Lonial S.

Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5. Review.

PMID:
20425421
19.

Treatment of newly diagnosed myeloma.

Palumbo A, Rajkumar SV.

Leukemia. 2009 Mar;23(3):449-56. doi: 10.1038/leu.2008.325. Epub 2008 Nov 13. Review.

20.

[Hematopoietic stem cell transplantation for multiple myeloma].

Kanda Y.

Rinsho Ketsueki. 2009 Oct;50(10):1420-6. Review. Japanese. No abstract available.

PMID:
19915350

Supplemental Content

Support Center